awmsg logo



bevacizumab (Avastin®)


Reference No. 2166

Publication date:
12/09/2017


Appraisal information

bevacizumab (Avastin®) 25 mg/ml concentrate for solution for infusion


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 08/02/2017
AWMSG meeting date: 15/03/2017
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0617
Ministerial ratification: 11/09/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Bevacizumab (Avastin®) is not recommended for use within NHS Wales in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download